Polycystic Ovarian Syndrome Treatment Market Share, Size, Growth, Opportunity and Forecast 2020-2025

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Polycystic Ovarian Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

Market Overview:

The global polycystic ovarian syndrome treatment market grew at a CAGR of around 6% during 2014-2019. Polycystic ovarian syndrome (PCOS) refers to a hormonal disorder that leads to the abnormal and excessive production of male hormones in females. It is characterized by hyperandrogenism, ovulatory dysfunction and the development of polycystic ovaries. The disorder can also cause acne, darkening of the skin, weight gain and missed or irregular menstrual cycles, leading to infertility and development of cysts or small fluid-filled sacs in the ovaries. Some of the commonly used treatment methods for regulating and managing PCOS include oral contraceptives, antiandrogens, insulin-sensitizing agents, antidepressants and anti-obesity medicines, along with various surgical procedures, such as ovarian wedge resection and laparoscopic ovarian drilling.

The increasing prevalence of PCOS across the globe represents one of the key factors driving the growth of the market. Furthermore, rising health consciousness and increasing awareness regarding the available treatment alternatives for PCOS are also driving the market growth. PCOS often leads to hirsutism, obesity, diabetes, infertility and other chronic ailments, which has enhanced the requirement for effective treatment alternatives to manage the disease efficiently. In line with this, widespread adoption of laparoscopic ovarian drilling, which involves the surgical triggering of ovulation in women, as an effective treatment for PCOS, is also contributing to the market growth. Additionally, various technological advancements, such as the development of improved pharmacological agents, including androgen suppressors and peripheral androgen blockers, are also favoring the market growth. Other factors, including rising healthcare expenditure of the individuals, along with extensive research and development (R&D) activities, are anticipated to drive the market further. Looking forward, IMARC Group expects the global polycystic ovarian syndrome treatment market to continue its moderate growth during the next five years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global polycystic ovarian syndrome treatment market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, drug class, surgery and distribution channel.

Breakup by Drug Class:

Oral Contraceptives
Antiandrogens
Insulin-sensitizing Agent
Antidepressant
Anti-obesity
Others

Breakup by Surgery:

Ovarian Wedge Resection
Laparoscopic Ovarian Drilling

Breakup by Distribution Channel:

Hospitals and Clinics
Retail Pharmacies
Online Stores
Others

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Company, Ferring B.V., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

How has the global polycystic ovarian syndrome treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global polycystic ovarian syndrome treatment market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the surgery type?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global polycystic ovarian syndrome treatment market and who are the key players?
What is the degree of competition in the industry?